ASCO 2023 | Potential predicative markers of immunotherapy response in GIST

Jonathan Trent, MD, PhD, University of Miami, Miami, FL, comments on the discovery of promising predicative markers of immunotherapy in patients gastrointestinal stromal tumor (GIST) in an analysis of a real-world dataset. Various DNA and RNA mutations, as well as copy number alterations were identified. KIT/PDGFRA mutations were particularly associated with increased inflamed stated, suggesting that this population may be more receptive to immunotherapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.